Today: 9 April 2026
Rivian stock slips in premarket as Tesla delivery report looms on year-end session
31 December 2025
1 min read

Rivian stock slips in premarket as Tesla delivery report looms on year-end session

NEW YORK, December 31, 2025, 07:29 ET — Premarket

  • Rivian shares edged lower in premarket trade after a 5.2% drop in the prior session.
  • EV peers Tesla and Lucid were also down ahead of Tesla’s quarterly deliveries due Friday.
  • Thin year-end trading and a New Year’s Day market holiday are sharpening focus on 2026 EV demand signals.

Rivian Automotive shares slipped in premarket trading on Wednesday, extending losses from the prior session as investors headed into the final trading day of 2025 with fresh anxiety about U.S. electric-vehicle demand.

The stock’s early move comes in a quiet, holiday-shortened week when price swings can look bigger than the headlines behind them. U.S. markets are closed on Thursday for New Year’s Day, compressing positioning into Wednesday’s session. Reuters

Sentiment across EV names has also been tied to Tesla’s quarterly deliveries report due on Friday. Reuters reported investors are bracing for a fourth-quarter decline after U.S. tax credits — a subsidy that lowers the effective purchase price — expired in September and competition intensified. Deutsche Bank analyst Edison Yu said the drop would be “driven largely by sales in North America and Europe.” Reuters

Rivian was down about 0.7% at $19.46 in premarket trading, after ending Tuesday at $19.59. The stock fell 5.2% in the previous regular session, according to MarketWatch data. MarketWatch

Tesla shares were down about 0.3% before the open, while Lucid Group was little changed, pointing to a softer tone for the EV group rather than an isolated move in Rivian. MarketWatch+1

Rivian’s stock has been volatile this month after the company showcased an autonomy and AI push, including a shift toward a custom self-driving chip and a paid driver-assistance feature set. Analysts have tied longer-term optimism to the more affordable R2 model line that Rivian has said is slated to launch in the first half of 2026. Reuters

With no new company filings or product announcements moving across the tape Wednesday morning, traders have treated Rivian as a high-beta EV name that can amplify sector mood swings. That dynamic tends to intensify when liquidity thins into the end of the year.

Investors are watching for demand read-throughs from Tesla’s delivery report and for any evidence that price cuts, incentives and shifting model mixes are changing the EV growth trajectory going into 2026. Rate expectations also remain a key driver for unprofitable or early-profitability companies, which can trade like long-duration assets when bond yields move.

For Rivian specifically, the next hard catalyst is its fourth-quarter results. Zacks expects Rivian to report earnings on Feb. 19, after the market close, though the company can still update timing. Zacks

Between now and then, investors will look for clues on deliveries, gross margin progress and cash use as Rivian prepares for the R2 launch cycle. Any updates on software features and paid driver-assistance uptake are also likely to be closely parsed because they can lift revenue per vehicle without requiring more factory output.

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:12 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
American Airlines stock dips in premarket as winter storm fallout keeps airlines in focus
Previous Story

American Airlines stock dips in premarket as winter storm fallout keeps airlines in focus

Denison Mines stock today: DNN flat in premarket as uranium sector eases into year-end session
Next Story

Denison Mines stock today: DNN flat in premarket as uranium sector eases into year-end session

Go toTop